The Wits HIV Research Group (WHRG) is a well-organized, highly effective Clinical Trial Unit (CTU) with an international reputation built on the successful conduct of NIH sponsored multi-centre trails, as well as its work with other international research groups. The WHRG consists of five Clinical Research Sites (CRSs) supported by a coordinating centre. This group has the capacity to undertake research in 5 high priority areas of HIV clinical trial research. The priority areas include Optimization of Clinical Management of HIV;Drug Development and Translational Research;HIV Prevention;Prevention of Mother to Child Transmission of HIV;HIV Vaccine Research and Development;and Microbicide Development. The CTU will link with five leadership networks (ACTG, IMPAACT, Microbicide Network, HVTN and PTN), maximizing scientific and recruitment opportunities by effectively integrating prevention, vaccine and therapeutic clinical trials in children, adolescents and adults. The unit will build on an established track record of the University of the Witwatersrand ACTU (Site#11101), PACTG (Site#8051), HPTN (Site#001-7) and a track record of international collaboration for microbicide research. In addition to our excellent record of research, this CTU contains four sites with letters confirming their status as selected sites for collaboration on four networks. The WHRG has a talented and skilled group of senior investigators with international reputations supported by enthusiastic research teams who are committed to HIV prevention in resource poor settings and the identification and management of acute HIV infections. The research team of the CTU has demonstrated an ability to work collaboratively with each other in all facets of the five networks and on PEPFAR initiatives. It is our aim to create a synergistic, pluri-potential CTU that is able to implement world-class research. In so doing, we also aim to achieve financial and operational efficiencies through centralizing and consolidating critical clinical research functions such as staff training, protocol implementation, regulatory compliance, IRB submission, pharmacy importation and data and quality management. The WHRG has close collaboration and support from the local, provincial and national Departments of Health, as well as from its own institutions. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069463-05
Application #
8020140
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M1))
Program Officer
Germuga, Donna E
Project Start
2007-03-15
Project End
2014-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
5
Fiscal Year
2011
Total Cost
$7,098,824
Indirect Cost
Name
Wits Health Consortium (Pty), Ltd
Department
Type
DUNS #
639391218
City
Johannesburg
State
Country
South Africa
Zip Code
Swindells, S; Gupta, A; Kim, S et al. (2018) Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003). Int J Tuberc Lung Dis 22:1016-1022
Goeieman, Bridgette J; Firnhaber, Cynthia S; Jong, Eefje et al. (2017) Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa. J Acquir Immune Defic Syndr 75:e59-e64
De Boni, Raquel B; Zheng, Lu; Rosenkranz, Susan L et al. (2016) Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals. Drug Alcohol Depend 159:174-80
La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58
Robertson, K; Jiang, H; Evans, S R et al. (2016) International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol 22:472-8
Kumarasamy, Nagalingeswaran; Aga, Evgenia; Ribaudo, Heather J et al. (2015) Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230. Clin Infect Dis 60:1552-8
Luetkemeyer, Anne F; Rosenkranz, Susan L; Lu, Darlene et al. (2015) Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis 60:1860-3
Gross, Robert; Zheng, Lu; La Rosa, Alberto et al. (2015) Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial. Lancet HIV 2:e12-9
Budgell, Eric P; Maskew, Mhairi; Long, Lawrence et al. (2015) Does most mortality in patients on ART occur in care or after lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr :
Erlandson, Kristine M; Taejaroenkul, Sineenart; Smeaton, Laura et al. (2015) A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings. Open Forum Infect Dis 2:ofv095

Showing the most recent 10 out of 40 publications